keine Finanzberatung

INSM · Insmed Incorporated

Rare-disease biotech — Arikayce and the brensocatib launch

Risiko 7/10 · HIGH RISK · priced-for-a-perfect-launch biotech · $126.29 ▼ 0.31%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $126.29
  • Market cap $27.6B
  • P/E (ttm) n/a
  • Div yield none
  • 52-wk range $90.39 – $212.75
  • Index rank — / #88

Wichtigste Risiken

  • Brensocatib launch underwhelms against sky-high hopes (Shareholders) — HIGH
  • Ongoing cash burn forces further dilution (Shareholders) — HIGH
  • Value concentrated in a handful of pipeline assets (Shareholders) — MED
  • Sustained insider selling into the rally (Shareholders) — MED

Fazit

The science is delivering, but the price already assumes commercial perfection — any launch friction and the premium deflates fast.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.